Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 507-510

  Ansari, Jawaher ^a   Fatima, Arfeen ^a   Fernando, Kieran ^a   Collins, Stuart ^b   James, Nicholas D ^a   Porfiri, Emilio ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Clear cell; Metastatic renal cell carcinoma; Sunitinib; Targeted agents; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; SUNITINIB; THYROXINE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER INCIDENCE; CANCER PATIENT; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEADACHE; HORMONE SUBSTITUTION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY METASTASIS; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN DISCOLORATION; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; GREAT BRITAIN; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77954378411     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000886     Document Type: Article

References (16)

1. Office for National Statistics: Registrations of cancer diagnosed in 2005, England, 2008.
2. Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med 353: 2477-2490, 2005.
3. Campbell SC, Flanigan RC and Clark JI: Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 4: 363-372, 2003.
4. Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295, 1993. (Pubitemid 23154478)
5. Fisher RI, Rosenberg SA and Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 (Suppl 1): 55-57, 2000.
6. Schwartz RN, Stover L and Dutcher J: Managing toxicities of high-dose interleukin-2. Oncology 16 (Suppl 13): 11-20, 2002.
7. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR and Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696, 1995.
8. Klapper JA, Downey SG, Smith FO, et al: High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma - a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113: 293-301, 2008.
9. Chow LQ and Eckhardt SG: Sunitinib - From rational design to clinical efficacy. J Clin Oncol 25: 884-896, 2007.
10. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524, 2006.
11. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
12. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
13. National Institute for Health and Clinical Excellence: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. (Technology appraisal 169). London, NICE, 2009. www.nice.org.uk/TA169.
14. Heng DY, Chi KN, Murray N, et al: A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 115: 776-783, 2009.
15. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24, 2006.
16. Bhojani N, Jeldres C, Patard JJ, et al: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53: 917-930, 2008.